SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte ...

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injectionTH103 was ...

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated ...

Kane Biotech Inc. (TSX-V:KNE) ('Kane Biotech”, 'Kane” or the 'Company”) announces that it presented new clinical and ...

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome. Read why KYTX ...

The combination of denifanstat and resmetirom was generally well-tolerated over the duration of the study, with no safety signals. No Serious Adverse Events (SAEs) occurred, and there were no ...

(11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD ...

MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with SitesSOUTH SAN FRANCISCO, Calif., Dec. 11 ...